Feng Zhi1, Naiyuan Shao1, Rong Wang1, Danni Deng1, Lian Xue1, Qiang Wang1, Yi Zhang1, Yimin Shi1, Xiwei Xia1, Suinuan Wang1, Qing Lan1, Yilin Yang1. 1. Modern Medical Research Center, Third Affiliated Hospital of Soochow University, Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W., Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital of Soochow University, Suzhou, China (N.S., Q.L.).
Abstract
BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers for human cancer. In the current study, we investigated the potential use of serum miRNAs as biomarkers for diagnosis and prognosis in a cohort of Chinese astrocytoma patients. METHODS: An initial screening of the circulating miRNA expression profile was performed on pooled serum samples from 10 preoperative patients and 10 healthy controls using a TaqMan low-density array. The selected serum miRNAs were then validated in 90 preoperative patients and 110 healthy controls who were randomly divided into a training set and a validation set. An additional double-blind test was performed in 50 astrocytomas and 50 controls to assess the serum miRNA-based biomarker accuracy in predicting astrocytoma. The differentially expressed miRNAs were evaluated in paired preoperative and postoperative serum samples from 73 astrocytoma patients. The correlation of the miRNA levels with survival in astrocytoma samples was estimated. RESULTS: Nine serum miRNAs were significantly increased in the astrocytoma patients. The biomarker composed of these 9 miRNAs had high sensitivity, specificity, and accuracy. These 9 miRNAs were markedly decreased in the serum after operation. The upregulation of miR-20a-5p, miR-106a-5p, and miR-181b-5p was associated with advanced clinical stages of astrocytoma. Kaplan-Meier survival analysis showed that the high expression of miR-19a-3p, miR-106a-5p, and miR-181b-5p was significantly associated with poor patient survival. Finally, the combined 3-miRNAs panel was an important prognostic predictor, independent of other clinicopathological factors. CONCLUSIONS: The results indicated the potential of serum miRNAs as novel diagnostic and prognostic biomarkers for human astrocytoma.
BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers for humancancer. In the current study, we investigated the potential use of serum miRNAs as biomarkers for diagnosis and prognosis in a cohort of Chinese astrocytomapatients. METHODS: An initial screening of the circulating miRNA expression profile was performed on pooled serum samples from 10 preoperative patients and 10 healthy controls using a TaqMan low-density array. The selected serum miRNAs were then validated in 90 preoperative patients and 110 healthy controls who were randomly divided into a training set and a validation set. An additional double-blind test was performed in 50 astrocytomas and 50 controls to assess the serum miRNA-based biomarker accuracy in predicting astrocytoma. The differentially expressed miRNAs were evaluated in paired preoperative and postoperative serum samples from 73 astrocytomapatients. The correlation of the miRNA levels with survival in astrocytoma samples was estimated. RESULTS: Nine serum miRNAs were significantly increased in the astrocytomapatients. The biomarker composed of these 9 miRNAs had high sensitivity, specificity, and accuracy. These 9 miRNAs were markedly decreased in the serum after operation. The upregulation of miR-20a-5p, miR-106a-5p, and miR-181b-5p was associated with advanced clinical stages of astrocytoma. Kaplan-Meier survival analysis showed that the high expression of miR-19a-3p, miR-106a-5p, and miR-181b-5p was significantly associated with poor patient survival. Finally, the combined 3-miRNAs panel was an important prognostic predictor, independent of other clinicopathological factors. CONCLUSIONS: The results indicated the potential of serum miRNAs as novel diagnostic and prognostic biomarkers for humanastrocytoma.
Authors: Yan Wang; Jian Gu; Jack A Roth; Michelle A T Hildebrandt; Scott M Lippman; Yuanqing Ye; John D Minna; Xifeng Wu Journal: Cancer Res Date: 2013-06-17 Impact factor: 12.701
Authors: Yirizhati Aili; Nuersimanguli Maimaitiming; Yusufu Mahemuti; Hu Qin; Yongxin Wang; Zengliang Wang Journal: Am J Cancer Res Date: 2020-12-01 Impact factor: 6.166
Authors: Zammam Areeb; Stanley S Stylli; Rachel Koldej; David S Ritchie; Tali Siegal; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor Journal: J Neurooncol Date: 2015-09-21 Impact factor: 4.130
Authors: Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244